Diabetes News

Endocrinology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Raskin P et al. – The repaglinide/metformin FDC BID regimen showed efficacy that was non–inferior to that of the rosiglitazone/metformin FDC BID regimen currently in clinical use and a more rapid reduction of HbA1c values. Thus, repaglinide/metformin FDC BID is a clinically feasible alternative to rosiglitazone/metformin FDC BID.

Today in Pharmacology/kinetics...keeping you current

The role of flow-mediated dilatation in the evaluation and development of antiatherosclerotic drugs
Current Opinion in Lipidology, 12/15/09

Thiazolidinediones and the liver in humans
Current Opinion in Lipidology, 12/15/09

Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin
Preventive Cardiology, 12/15/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address